GeNeuro picked BNP Paribas Securities Services to manage the operational aspects of its recent initial public offering (IPO) on the Euronext Paris stock exchange.
Created in 2006 as a spin-off from bioMérieux, GeNeuro is a Swiss biopharmaceutical company. GeNeuro raised approximatively EUR 33 million through its IPO. The proceeds will be used to strengthen GeNeuro’s capital structure and finance its work on multiple sclerosis and new autoimmune indications as well as its growth in Europe and the United States.
The bank provided management and administration services for the new shares issuance by simplifying and securing the different processes. Post-IPO, it is GeNeuro’s information agent, keeping market participants up to date with any changes in the structure of GeNeuro’s capital; it will also provide GeNeuro with dividend payment services.
“We thank BNP Paribas Securities Services for its proactive and effective approach to this IPO, in particular in terms of navigating the complexities of this first listing of a Swiss company on Euronext Paris. We are very satisfied with the choice we made,” said Miguel Payró, chief financial ffficer of GeNeuro.
Pierre Jond, head of Corporate Trust Services at BNP Paribas Securities Services said: “We are delighted to have successfully completed this listing of an international life science company, the first major listing in Paris in 2016.”